Summary & Overview
HCPCS J9045: Injection, Carboplatin, 50 mg
HCPCS Level II code J9045 denotes a 50 mg unit of carboplatin administered as an injectable chemotherapeutic agent. Carboplatin is widely used in oncology for several malignancies; accurate coding of units is critical for clinical documentation, billing, and aggregate drug utilization monitoring. Nationally, unit-based HCPCS codes for chemotherapy drugs like J9045 affect provider reimbursement, drug spending, and payer coverage policies.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for carboplatin administration, typical sites of service where the code is billed, and the payers commonly responsible for covering services billed with this code. The publication outlines benchmark elements and common billing considerations related to unit-based chemotherapy coding, and highlights where input for policy updates or payer-specific coverage rules may be relevant.
This summary is intended for billing managers, practice administrators, and policy analysts who need a national-level briefing on HCPCS Level II code J9045, including clinical purpose, billing context, and the payers typically involved.
Billing Code Overview
HCPCS Level II code J9045 represents Injection, carboplatin, 50 mg. This code describes administration of the chemotherapeutic agent carboplatin in 50 milligram units.
-
Service type: Drug administration (intravenous chemotherapy infusion or injection)
-
Typical site of service: Infusion center, outpatient oncology clinic, hospital outpatient department, or other settings where parenteral chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor (for example, ovarian, lung, or head and neck cancer) scheduled to receive systemic chemotherapy with carboplatin. The medication J9045 (Injection, carboplatin, 50 mg) is administered by an oncology-specialty infusion clinic or hospital outpatient infusion center. Workflow: patient arrives for a planned cycle, vital signs and laboratory results (including CBC and renal function) are reviewed to confirm eligibility for chemotherapy. A pharmacist verifies dose calculation based on area under the curve (AUC) and renal function, prepares J9045 in the appropriate concentration and volume under sterile conditions, and the infusion nurse obtains consent, confirms patient identity and premedication orders, establishes intravenous access (peripheral IV or implanted port), and administers carboplatin over the ordered infusion time. Post-infusion monitoring includes observation for infusion reactions, assessment of nausea control, and documentation of administered drug lot number and amount. Billing is submitted to the patient’s payor with the appropriate HCPCS code J9045 and any applicable modifier(s) reflecting circumstances such as supervision, dosage form, or administration complexity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |